<Record><identifier xmlns="http://purl.org/dc/elements/1.1/">URN:NBN:SI:doc-ACDJVZNG</identifier><date>2018</date><creator>Gavrič, Ana Uršula</creator><creator>Jaki Mekjavić, Polona</creator><creator>Ocvirk, Janja</creator><relation>documents/doc/A/URN_NBN_SI_doc-ACDJVZNG_001.pdf</relation><relation>documents/doc/A/URN_NBN_SI_doc-ACDJVZNG_001.txt</relation><format format_type="issue">2</format><format format_type="volume">52</format><format format_type="type">article</format><format format_type="extent">str. 213-219</format><identifier identifier_type="ISSN">1318-2099</identifier><identifier identifier_type="COBISSID_HOST">2876795</identifier><identifier identifier_type="URN">URN:NBN:SI:doc-ACDJVZNG</identifier><language>eng</language><publisher>Association of Radiology and Oncology</publisher><source>Radiology and oncology (Ljubljana)</source><rights>BY</rights><subject language_type_id="eng">eye</subject><subject language_type_id="slv">inhibitor MEK</subject><subject language_type_id="eng">MEK inhibitor</subject><subject language_type_id="eng">MEKAR</subject><subject language_type_id="eng">metastatic malignant melanoma</subject><subject language_type_id="slv">metastatski maligni melanom</subject><subject language_type_id="slv">oči</subject><subject language_type_id="slv">zaviralec MEK</subject><title>Ocular changes in metastatic melanoma patients treated with MEK inhibitor cobimetinib and BRAF inhibitor vemurafenib</title></Record>